MBX · MBX Biosciences, Inc.
$68.57
+1.49 (+2.22%)
At close · Aug 14
Market Cap
$3.30B
Shares
48.16M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| P. Kent Hawryluk | President and Chief Executive Officer | $2,990,867 |
| Richard Bartram | Former Chief Financial Officer | $1,496,275 |
| Salomon Azoulay | Chief Medical Officer | $1,474,978 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Salomon Azoulay | Chief Medical Officer | $3,095,920 |
| P. Kent Hawryluk | President and Chief Executive Officer | $2,235,317 |
| Richard Bartram | Chief Financial Officer | $1,153,568 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| P. Kent Hawryluk | President and Chief Executive Officer | $4,862,064 |
| Richard Bartram | Chief Financial Officer | $1,051,106 |
| Salomon Azoulay | Chief Medical Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Steven Hoerter | President and Chief Executive Officer and principal executive officer | Appointed | 2026-07-13 |
| Kent P. Hawryluk | member of the Board | Resigned | 2026-07-13 |
| Kent P. Hawryluk | Chief Executive Officer | Resigned | 2026-07-13 |
| Edward T. Mathers | Class II Director | Appointed | 2026-06-05 |
| Patrick J. Heron | Class II Director | Appointed | 2026-06-05 |
| John Smither | Interim Chief Financial Officer | Appointed | 2026-02-27 |
| Richard Bartram | Chief Financial Officer | Resigned | 2026-02-27 |
| Laurie Stelzer | director | Appointed | 2026-01-22 |
| Tiba Aynechi | chairperson of the Audit Committee | Appointed | 2025-11-06 |
| Ed Mathers | Audit Committee member | Appointed | 2025-11-06 |
| Steven Hoerter | executive chairperson of the Board | Appointed | 2025-11-06 |
| James M. Cornelius | member of the Company's board of directors | Resigned | 2025-11-06 |
| P. Kent Hawryluk | Class I director | Appointed | 2025-06-06 |
| Tiba Aynechi, Ph.D. | Class I director | Appointed | 2025-06-06 |
| Steven L. Hoerter | director | Appointed | 2025-04-07 |
Key facts
CIK
1776111
CUSIP
55287L101
13F (30d)
175 filings
171 filers
Visit website
Investor relations